Dear Editor,Colorectal cancer(CRC)is the second leading cause of cancer death according to the World Health Organization.Patients with inflammatory bowel disease(IBD),ulcerative colitis(UC)or Crohn’s disease(CD)are a...Dear Editor,Colorectal cancer(CRC)is the second leading cause of cancer death according to the World Health Organization.Patients with inflammatory bowel disease(IBD),ulcerative colitis(UC)or Crohn’s disease(CD)are at increased risk of developing colitis-associated CRC(CAC)[1];however,our understanding of the inflammationcancer interplay at the molecular level is still limited.展开更多
基金the MCIN/AEI/10.13039/501100011033(PID2019-108349RB-100 and SAF2016-79792R)to AC and JJSEVillum Foundation,grant no.13152 to KAby Agencia Estatal de Investigación(PID2019-104867RBI00/AEI/10.13039/501100011033)and the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional(CIBERONC/CB16/12/00273 and ICI20/00057)to AM and AB.PF received MCIN FPI fellowship(BES-2017-080139).
文摘Dear Editor,Colorectal cancer(CRC)is the second leading cause of cancer death according to the World Health Organization.Patients with inflammatory bowel disease(IBD),ulcerative colitis(UC)or Crohn’s disease(CD)are at increased risk of developing colitis-associated CRC(CAC)[1];however,our understanding of the inflammationcancer interplay at the molecular level is still limited.